Cost-effectiveness of Samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal;Análise custo-efectividade do Samário-153-EDTMP versus terapêutica convencional da dor em doentes com metástases ósseas múltiplas dolorosas em Portugal

Acta Medica Portuguesa

Volumn 19, Issue 5, 2006, Pages 421-426

  Macedo, Ana ^a   Araújo, António ^a   Melo, Fernando Carvalho ^a   Nunes, Garção ^a   Cantinho, Guilhermina ^a   Amorim, Inêz ^a  

^a NONE

Author keywords

Cost effectiveness; Multiple bone metastasis; Pain; Prostate cancer; Samarium 153 EDTMP

Indexed keywords

SAMARIUM 153; ANALGESIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER PAIN; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MALE; PORTUGAL; PROSTATE CANCER; BONE TUMOR; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; METASTASIS; PAIN; PATHOLOGY; PROSTATE TUMOR; TREATMENT FAILURE;

ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PORTUGAL; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 34249666263     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. PINHEIRO PS, TYCZYNSKI JE, BRAY F, AMADO J, MATOS E, PARKIN DM: Cancer incidence and mortality in Portugal. Eur J Cancer 2003;39(17):2507-20
2. AUCLERC G, ANTOINE EC, CAJFINGER F, BRUNET-POMMEYROL A, AGAZIA C, KHAYAT D: Management of advanced prostate cancer. Oncologist 2000;5(1):36-44
3. PANDIT-TASKAR N, BATRAKI M, DIVGI CR: Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45(8):1358-65
4. SERAFINI AN: Therapy of metastatic bone pain. J Nucl Med. 2001;42(6):895-906
5. SARTOR O, REID RH, HOSKIN PJ et al: Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urol 2004:63(5):940-5
6. European Public Assessment Report (EPAR). p. 12
7. SILVA E, PINTO G, SAMPAIO C, PEREIRA J, DRUMMOND M, TRINDADE R: Orientações Metodológicas para Estudos de Avaliação Económica de Medicamentos. Ed INFARMED. Lisboa 1999
8. National Therapeutic Index, 2004, April; GDH (custos oficiais publicados), 2003, February (última actualização); IGIF - Instituto de Gestão Informática e Financeira da Saúde, 2004; Honorários médicos, Ordem dos Médicos 1997 (última actualização); informação directa da Schering Lusitana; informação directa dos hospitais (peritos)
9. FRICKE FU et al: Kosteneffektivität von Samarium-153-EDTMP im Vergleich zur konventionellen Schmerztherapie, in: Nuklearmedizin 2004:43:A19
10. RESCHE I, CHATAL JF, PECKING A et al: A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91